The generic name of fenmadone is Estradiol Tablets/Estradiol Dydrogesterone Tablets Complex Packaging, and Breast Enlargement Category 3 refers to Breast BI-RADS Classification Category 3, which is usually not allowed for patients to take Estradiol Tablets/Estradiol Dydrogesterone Tablets Complex Packaging. For breast BI-RADS classification category 3, it often suggests that the breast nodule benign may be large and malignant may be less than 2%. Usually patients do not need to take Estradiol Tablets/Estradiol Dydrogesterone Tablets Composite Packaging because the drug belongs to the hormone class of drugs, and patients may further aggravate breast hyperplasia after using the drug, which may have an impact on the quality of life and health. Estradiol Tablets/Estradiol Dydrogesterone Tablets Composite Packaging is commonly used in clinical practice for the treatment of perimenopausal syndrome due to natural or postoperative menopause. It is contraindicated for special populations with known or suspected history of breast cancer, estrogen-progestogen-dependent tumors, and unexplained genital tract bleeding, excessive endometrial hyperplasia, and so on. It is recommended that patients use medication under the guidance of a physician, and should not use drugs or prescriptions on their own. If the patient is not feeling well after using the medicine, he/she should stop using the medicine and consult a doctor in time.